

Nebraska State Department of Insurance and I would like to give you some of the things that he said in regard to insurance. "Presently most laetrile treatments are not covered by cancer policies because laetrile is administered on an out patient basis. If laetrile were administered in a hospital, many policies might cover it assuming that it were administered legally to a terminally ill patient in injection form. The Insurance Department would not be able to prohibit an exclusionary rider thus a company could exclude laetrile coverage in new policies if it so choose. It would be up to the discretion of the company. It is important to remember that, number one, the companies might not have to pay for laetrile treatments if their policy does not cover drugs and, number two, the State Insurance Department allows the company to exclude laetrile in new policy. It is also important to note that even with the passage of LB 382 many laetrile treatments will not be covered because they are not administered in a hospital but rather as an out patient basis." Now the information also that Senator Cullan passed out to you I would like to quickly go over those if I have time. Number one, he says that laetrile is ineffective as a cancer treatment. The effect of laetrile has neither been conclusively established nor indefinitely rejected largely because the FDA has blocked the testing of laetrile on humans. In 1970 the FDA denied a request to conduct laetrile tests on volunteer humans. Judge Bohanon confirms this in his opinion. He says, "The current debate is fierce. The issue appears largely unresolved as to laetrile's true effectiveness, in large part because the FDA has prevented testing on humans." The opponents of laetrile have very little firsthand knowledge of its effect on humans, "While the record reveals," and Judge Bohanon goes on to say this, "While the record reveals an impressive consensus among the nation's large medical and cancer fighting institutions as to laetrile's effectiveness, a disconcerting dirth of actual experience with the substance by such detractors is revealed." Some tests also disputed have shown laetrile to be effective in treating tumors in test animals. Some of these tests were conducted by Dr. Sugiura at the Sloan-Kettering Research Institute. It is still my belief that laetrile cures metathesis. Further, Dr. Harold Manner of Loyola University testified at the LB 382 hearing on March 5th concerning his statements demonstrating the effect of laetrile in treating tumors in test animals. He used 550 animals and his conclusion was, "I did get substantial regression of tumors with the use of laetrile." I don't know whether he has brought it up but I think that in his information he passed out, Senator Cullan mentions the fact, and he did last time